themiller schreef op 16 juli 2020 09:53:
Was deze al eens langsgekomen? angioedemanews.com/2020/06/19/rucones...
Overall, the models suggested Ruconest as the most cost-effective of the four treatments analyzed, at an estimated $12,905 per attack. This was followed by Berinert ($14,668 per attack), Firazyr ($14,806 per attack), and Kalbitor ($21,068 per attack).
The effectiveness of each therapy also was estimated using a model that represented the amount of time per year during which an individual was not dealing with an HAE attack — with more effective therapies conferring less time spent with attacks. Due to the particular mathematics of the model, a maximum score of 0.83 was possible (indicating no attacks).
Ruconest had the highest estimated efficacy with a score of 0.806, followed by Kalbitor at 0.792, then Berinert at 0.769, and Firazyr at 0.765.
“This model finds that rhC1-INH [Ruconest] is both less costly and more effective than the remaining comparators and therefore represents the dominant therapy,” the researchers wrote.